We therefore hypothesized that, given the production of Shh and IL-6 in breast tumor microenvironment, serum Shh and IL-6 are abundant and might be detectable in the general circulation, and, if highly abundant in blood sera, would specify poor outcome and prognosis in breast cancer patients. This evidence concerns the gene IL6 and breast carcinoma.